1
HESI RN ADVANCED PHARMACOLOGY
EXAM Actual Exam 2026/2027 Complete
Questions and Verified Answers with
Rationales Already Graded A+ Pass
Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Q1: A patient is started on warfarin. The nurse knows that warfarin's anticoagulant effect is
monitored using which laboratory value, and what is the therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH and occasionally unfractionated heparin. Bleeding time (D) is
not used to monitor warfarin therapy.
Q2: A patient with chronic pain is prescribed codeine for postoperative pain management. The
nurse notes the patient reports minimal pain relief. Genetic testing reveals the patient is a
CYP2D6 poor metabolizer. What is the pharmacological explanation for this therapeutic failure?
A. The patient has developed tolerance to opioid analgesics
B. Codeine is a prodrug requiring CYP2D6 metabolism to morphine for analgesic effect.
[CORRECT]
C. The patient has increased hepatic clearance of codeine
D. Codeine undergoes extensive first-pass metabolism in the gut
,2
Correct Answer: B
Rationale: Codeine is a prodrug with minimal intrinsic analgesic activity; it requires metabolism
via the CYP2D6 enzyme to convert to morphine, which provides the analgesic effect (B). Poor
metabolizers cannot efficiently convert codeine to morphine, resulting in inadequate pain relief.
This is not tolerance (A), and poor metabolizers have reduced, not increased, metabolism (C).
First-pass metabolism (D) occurs in the liver, not the gut.
Q3: A patient taking phenytoin for seizure control is started on fluconazole for a fungal infection.
The nurse should monitor for which potential drug interaction?
A. Decreased phenytoin levels due to CYP450 enzyme induction
B. Increased phenytoin toxicity due to CYP2C9/2C19 inhibition. [CORRECT]
C. Decreased fluconazole absorption due to phenytoin
D. Increased risk of hepatotoxicity from fluconazole alone
Correct Answer: B
Rationale: Fluconazole is a potent inhibitor of CYP2C9 and CYP2C19 enzymes, which are
responsible for phenytoin metabolism (B). This inhibition decreases phenytoin clearance, leading
to increased serum levels and potential toxicity (nystagmus, ataxia, confusion). Phenytoin is an
enzyme inducer, not inhibitor (A). Phenytoin does not significantly affect fluconazole absorption
(C). While hepatotoxicity is possible with fluconazole, the primary concern is the
pharmacokinetic interaction with phenytoin.
Q4: Which factor would most significantly increase the volume of distribution (Vd) of a
hydrophilic drug like gentamicin?
A. Increased adipose tissue in obesity
B. Third-spacing of fluids into the peritoneum. [CORRECT]
C. Decreased plasma protein binding
D. Increased hepatic blood flow
Correct Answer: B
Rationale: Hydrophilic drugs like aminoglycosides distribute poorly into adipose tissue and
primarily remain in extracellular fluid. Third-spacing (ascites, peritonitis, edema) increases the
apparent volume of distribution for hydrophilic drugs (B), potentially requiring higher loading
doses. Obesity (A) increases Vd for lipophilic drugs, not hydrophilic ones. Protein binding (C)
affects drug distribution but gentamicin is minimally protein-bound. Hepatic blood flow (D)
affects metabolism, not Vd of hydrophilic drugs.
,3
Q5: A patient receives a drug with a half-life of 8 hours. Approximately how long will it take to
reach steady-state concentration with continuous administration?
A. 8 hours
B. 24 hours
C. 40 hours. [CORRECT]
D. 80 hours
Correct Answer: C
Rationale: Steady-state concentration is typically reached after 4-5 half-lives of a drug. With a
half-life of 8 hours, steady-state would be achieved in approximately 32-40 hours (C). One half-
life (A) represents 50% elimination. Three half-lives (B) achieve 87.5% of steady-state. Ten half-
lives (D) far exceed the time needed for steady-state and represent near-complete drug
elimination.
Q6: A nurse is teaching a patient about grapefruit juice interactions. Which statement by the
patient indicates understanding of the mechanism?
A. "Grapefruit juice induces liver enzymes, causing faster drug metabolism"
B. "Grapefruit juice inhibits intestinal CYP3A4, increasing bioavailability of susceptible drugs."
[CORRECT]
C. "Grapefruit juice increases renal excretion of medications"
D. "Grapefruit juice binds to drugs in the stomach, preventing absorption"
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit CYP3A4 enzymes
in the intestinal wall (not the liver), decreasing first-pass metabolism and increasing
bioavailability of susceptible drugs like statins, calcium channel blockers, and
immunosuppressants (B). It does not induce enzymes (A), affect renal excretion (C), or bind
drugs in the stomach (D).
Q7: A patient with G6PD deficiency develops hemolytic anemia after receiving primaquine. This
reaction represents which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre/idiosyncratic). [CORRECT]
C. Type C (chronic use)
D. Type D (delayed)
Correct Answer: B
Rationale: Type B reactions are bizarre, idiosyncratic reactions that occur in susceptible
, 4
individuals due to genetic or immunologic factors, unpredictable by the drug's pharmacology
(B). G6PD deficiency is a genetic polymorphism causing primaquine-induced hemolysis. Type A
reactions (A) are dose-related and predictable. Type C (C) relates to long-term use (e.g.,
corticosteroid-induced osteoporosis). Type D (D) involves carcinogenic or teratogenic effects
with delayed onset.
Q8: Which drug exhibits zero-order kinetics at therapeutic doses, meaning a constant amount
(not percentage) of drug is eliminated per unit time?
A. Aspirin at low doses
B. Phenytoin at therapeutic concentrations. [CORRECT]
C. Penicillin G
D. Metformin
Correct Answer: B
Rationale: Phenytoin demonstrates capacity-limited (zero-order) kinetics at therapeutic
concentrations because its metabolism via CYP2C9/2C19 becomes saturated (B). This means a
constant amount is eliminated per hour, not a constant percentage, making dosing adjustments
critical. Aspirin shows zero-order kinetics only at high anti-inflammatory doses, not low doses
(A). Penicillin (C) and metformin (D) follow first-order kinetics where elimination is
proportional to concentration.
Q9: A patient receives naloxone for morphine overdose. Naloxone is classified as which type of
receptor interaction?
A. Full agonist at mu-opioid receptors
B. Competitive antagonist at mu-opioid receptors. [CORRECT]
C. Partial agonist at mu-opioid receptors
D. Inverse agonist at mu-opioid receptors
Correct Answer: B
Rationale: Naloxone is a pure competitive antagonist at mu-opioid receptors, binding with high
affinity but producing no intrinsic activity, thereby displacing agonists like morphine and
reversing respiratory depression (B). It is not an agonist (A) or partial agonist (C). Inverse
agonists (D) produce opposite effects of agonists at constitutively active receptors, which is not
naloxone's mechanism.
Q10: A patient with renal failure requires dosing adjustment for which drug primarily eliminated
unchanged by the kidneys?
HESI RN ADVANCED PHARMACOLOGY
EXAM Actual Exam 2026/2027 Complete
Questions and Verified Answers with
Rationales Already Graded A+ Pass
Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Q1: A patient is started on warfarin. The nurse knows that warfarin's anticoagulant effect is
monitored using which laboratory value, and what is the therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH and occasionally unfractionated heparin. Bleeding time (D) is
not used to monitor warfarin therapy.
Q2: A patient with chronic pain is prescribed codeine for postoperative pain management. The
nurse notes the patient reports minimal pain relief. Genetic testing reveals the patient is a
CYP2D6 poor metabolizer. What is the pharmacological explanation for this therapeutic failure?
A. The patient has developed tolerance to opioid analgesics
B. Codeine is a prodrug requiring CYP2D6 metabolism to morphine for analgesic effect.
[CORRECT]
C. The patient has increased hepatic clearance of codeine
D. Codeine undergoes extensive first-pass metabolism in the gut
,2
Correct Answer: B
Rationale: Codeine is a prodrug with minimal intrinsic analgesic activity; it requires metabolism
via the CYP2D6 enzyme to convert to morphine, which provides the analgesic effect (B). Poor
metabolizers cannot efficiently convert codeine to morphine, resulting in inadequate pain relief.
This is not tolerance (A), and poor metabolizers have reduced, not increased, metabolism (C).
First-pass metabolism (D) occurs in the liver, not the gut.
Q3: A patient taking phenytoin for seizure control is started on fluconazole for a fungal infection.
The nurse should monitor for which potential drug interaction?
A. Decreased phenytoin levels due to CYP450 enzyme induction
B. Increased phenytoin toxicity due to CYP2C9/2C19 inhibition. [CORRECT]
C. Decreased fluconazole absorption due to phenytoin
D. Increased risk of hepatotoxicity from fluconazole alone
Correct Answer: B
Rationale: Fluconazole is a potent inhibitor of CYP2C9 and CYP2C19 enzymes, which are
responsible for phenytoin metabolism (B). This inhibition decreases phenytoin clearance, leading
to increased serum levels and potential toxicity (nystagmus, ataxia, confusion). Phenytoin is an
enzyme inducer, not inhibitor (A). Phenytoin does not significantly affect fluconazole absorption
(C). While hepatotoxicity is possible with fluconazole, the primary concern is the
pharmacokinetic interaction with phenytoin.
Q4: Which factor would most significantly increase the volume of distribution (Vd) of a
hydrophilic drug like gentamicin?
A. Increased adipose tissue in obesity
B. Third-spacing of fluids into the peritoneum. [CORRECT]
C. Decreased plasma protein binding
D. Increased hepatic blood flow
Correct Answer: B
Rationale: Hydrophilic drugs like aminoglycosides distribute poorly into adipose tissue and
primarily remain in extracellular fluid. Third-spacing (ascites, peritonitis, edema) increases the
apparent volume of distribution for hydrophilic drugs (B), potentially requiring higher loading
doses. Obesity (A) increases Vd for lipophilic drugs, not hydrophilic ones. Protein binding (C)
affects drug distribution but gentamicin is minimally protein-bound. Hepatic blood flow (D)
affects metabolism, not Vd of hydrophilic drugs.
,3
Q5: A patient receives a drug with a half-life of 8 hours. Approximately how long will it take to
reach steady-state concentration with continuous administration?
A. 8 hours
B. 24 hours
C. 40 hours. [CORRECT]
D. 80 hours
Correct Answer: C
Rationale: Steady-state concentration is typically reached after 4-5 half-lives of a drug. With a
half-life of 8 hours, steady-state would be achieved in approximately 32-40 hours (C). One half-
life (A) represents 50% elimination. Three half-lives (B) achieve 87.5% of steady-state. Ten half-
lives (D) far exceed the time needed for steady-state and represent near-complete drug
elimination.
Q6: A nurse is teaching a patient about grapefruit juice interactions. Which statement by the
patient indicates understanding of the mechanism?
A. "Grapefruit juice induces liver enzymes, causing faster drug metabolism"
B. "Grapefruit juice inhibits intestinal CYP3A4, increasing bioavailability of susceptible drugs."
[CORRECT]
C. "Grapefruit juice increases renal excretion of medications"
D. "Grapefruit juice binds to drugs in the stomach, preventing absorption"
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit CYP3A4 enzymes
in the intestinal wall (not the liver), decreasing first-pass metabolism and increasing
bioavailability of susceptible drugs like statins, calcium channel blockers, and
immunosuppressants (B). It does not induce enzymes (A), affect renal excretion (C), or bind
drugs in the stomach (D).
Q7: A patient with G6PD deficiency develops hemolytic anemia after receiving primaquine. This
reaction represents which type of adverse drug reaction?
A. Type A (augmented)
B. Type B (bizarre/idiosyncratic). [CORRECT]
C. Type C (chronic use)
D. Type D (delayed)
Correct Answer: B
Rationale: Type B reactions are bizarre, idiosyncratic reactions that occur in susceptible
, 4
individuals due to genetic or immunologic factors, unpredictable by the drug's pharmacology
(B). G6PD deficiency is a genetic polymorphism causing primaquine-induced hemolysis. Type A
reactions (A) are dose-related and predictable. Type C (C) relates to long-term use (e.g.,
corticosteroid-induced osteoporosis). Type D (D) involves carcinogenic or teratogenic effects
with delayed onset.
Q8: Which drug exhibits zero-order kinetics at therapeutic doses, meaning a constant amount
(not percentage) of drug is eliminated per unit time?
A. Aspirin at low doses
B. Phenytoin at therapeutic concentrations. [CORRECT]
C. Penicillin G
D. Metformin
Correct Answer: B
Rationale: Phenytoin demonstrates capacity-limited (zero-order) kinetics at therapeutic
concentrations because its metabolism via CYP2C9/2C19 becomes saturated (B). This means a
constant amount is eliminated per hour, not a constant percentage, making dosing adjustments
critical. Aspirin shows zero-order kinetics only at high anti-inflammatory doses, not low doses
(A). Penicillin (C) and metformin (D) follow first-order kinetics where elimination is
proportional to concentration.
Q9: A patient receives naloxone for morphine overdose. Naloxone is classified as which type of
receptor interaction?
A. Full agonist at mu-opioid receptors
B. Competitive antagonist at mu-opioid receptors. [CORRECT]
C. Partial agonist at mu-opioid receptors
D. Inverse agonist at mu-opioid receptors
Correct Answer: B
Rationale: Naloxone is a pure competitive antagonist at mu-opioid receptors, binding with high
affinity but producing no intrinsic activity, thereby displacing agonists like morphine and
reversing respiratory depression (B). It is not an agonist (A) or partial agonist (C). Inverse
agonists (D) produce opposite effects of agonists at constitutively active receptors, which is not
naloxone's mechanism.
Q10: A patient with renal failure requires dosing adjustment for which drug primarily eliminated
unchanged by the kidneys?
